PsiOxus Therapeutics appoints new CEO
PsiOxus Therapeutics, an Oxford-based clinical-stage biotechnology company, has appointed Howard Davis PhD as Chief Executive Officer.
Dr Davis will be based in the greater Boston metropolitan area where he will establish the company’s U.S. operations. The appointment replaces interim CEO Priya Mande who has been made the new role of Chief Operating Officer and UK President.
Dr Davis brings more than 20 years of experience to PsiOxus, having served in diverse roles across VC-backed biotech and large pharma companies spanning a broad range of therapeutic areas including neuroscience, ophthalmology, immunology, and rare diseases.
Duncan Higgons, Chairman of the Board of PsiOxus, said: “Howard joins us at a critical stage for PsiOxus, as we rapidly progress our NG-350A and NG-641 immuno-oncology programs through early clinical studies and leverage our novel T-SIGn® platform to further expand our pipeline.
“We believe Howard’s exceptional leadership skills combined with his extensive experience across all phases of the product development lifecycle will help PsiOxus realize the full promise of its platform."
Read more - The most innovative life sciences companies in the Thames Valley
Most recently he worked with Atlas Venture on the launch of Third Harmonic Bio, a clinical stage immunology company where he served as COO with responsibility for business development, new product planning, finance, HR, legal / IP, and IT.
During his tenure, he spearheaded fundraising efforts that secured $155 million in private financing to support the company’s advancement of its lead clinical stage molecule.
Earlier in his career, he served as a Principal at Flagship Pioneering where he focused on expanding the firm’s portfolio of corporate strategic partnerships while also supporting new company creation efforts.
Dr Davis said: “PsiOxus has developed a groundbreaking platform in the T-SIGn® viral vector system and the company’s pipeline has the potential to truly revolutionize the treatment of solid tumors.
“With the team’s rapid advancement of the NG-350A and NG-641 programs into the clinic, we anticipate a significant flow of clinical data in the coming quarters.”
Read more - Life sciences property occupancy in South East to surpass last year's total
